The PI3K p110alpha isoform regulates endothelial adherens junctions via Pyk2 and Rac1

Citation for published version:
Cain, RJ, Varhaesebroeck, B & Ridley, AJ 2010, 'The PI3K p110alpha isoform regulates endothelial adherens junctions via Pyk2 and Rac1', Journal of Cell Biology, vol. 188, no. 6, pp. 863-76. https://doi.org/10.1083/jcb.200907135

Digital Object Identifier (DOI):
10.1083/jcb.200907135

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Journal of Cell Biology

Publisher Rights Statement:
Copyright © 2010 Cain et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
The PI3K \( p110\alpha \) isoform regulates endothelial adherens junctions via Pyk2 and Rac1

Robert J. Cain, Bart Vanhaesebroeck, and Anne J. Ridley

1Randall Division of Cell and Molecular Biophysics, King’s College London, London SE1 1UL, England, UK
2Centre for Cell Signalling, Institute of Cancer, Queen Mary, University of London, London EC1M 6BQ, England, UK

Introduction

Endothelial cell–cell junctions control efflux of small molecules and leukocyte transendothelial migration (TEM) between blood and tissues. Inhibitors of phosphoinositide 3-kinases (PI3Ks) increase endothelial barrier function, but the roles of different PI3K isoforms have not been addressed. In this study, we determine the contribution of each of the four class I PI3K isoforms (\( p110\alpha, \beta, \gamma, \) and \( \delta \)) to endothelial permeability and leukocyte TEM. We find that depletion of \( p110\alpha \) but not other \( p110 \) isoforms decreases TNF-induced endothelial permeability, Tyr phosphorylation of the adherens junction protein vascular endothelial cadherin (VE-cadherin), and leukocyte TEM. \( p110\alpha \) selectively mediates activation of the Tyr kinase Pyk2 and GTPase Rac1 to regulate barrier function. Additionally, \( p110\alpha \) mediates the association of VE-cadherin with Pyk2, the Rac guanine nucleotide exchange factor Tiam-1 and the p85 regulatory subunit of PI3K. We propose that \( p110\alpha \) regulates endothelial barrier function by inducing the formation of a VE-cadherin–associated protein complex that coordinates changes to adherens junctions with the actin cytoskeleton.

© 2010 Cain et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
Tiam-1 (van Buul et al., 2005; Bäumer et al., 2006; Allingham et al., 2007; Turrowski et al., 2008). Proinflammatory mediators also stimulate changes in cell shape and actin stress fiber reorganization (Essl er et al., 1998; Hordijk et al., 1999), which are proposed to aid junctional disruption during paracellular TEM by increasing tensile force on cell–cell junctions (Wójc iak-Sto thard and Ridley, 2002; Millán and Ridley, 2005). Several signaling pathways have been implicated in these responses, including the Rho GTPases Rho and/or Rac, the Rho target ROCK (Rho-associated, coiled-coil–containing kinase), Src kinases, and phosphoinositi de 3-kinases (PI3Ks; Vouret-Craviari et al., 1998; Wójc iak-Sto thard et al., 1998; Lam pugnani et al., 2002; van Wetering et al., 2003; Birukova et al., 2005; Kilic et al., 2006; Birukov, 2009; Hu and Minshall, 2009).

PI3Ks affect multiple steps of the inflammatory process, including leukocyte TEM (Carman and Springer, 2004; Puri et al., 2004, 2005; Nakhaei-Nejad et al., 2007; Li et al., 2008; Serban et al., 2008). Class I (A and B) PI3Ks consist of a 110-kD catalytic subunit and a regulatory subunit. Class IA comprises three catalytic isoforms, p110α, -β, and -δ, bound to one of five regulatory subunits (p85α and -β, p55α and -γ, and p50α), whereas class IB comprises the p110γ catalytic isoform bound to either a p101 or p84 regulatory subunit (Suire et al., 2005; Cain and Ridley, 2009). Class IA isoforms are usually activated by binding of the regulatory subunit to Tyr phosphorylated proteins, whereas class IB PI3K is activated by G protein–coupled receptors (Vanhaesebroeck et al., 2001). Studies in gene-targeted mice have shown that class IA PI3Ks, particularly p110α, are important for vascular development and angiogenesis (Graupera et al., 2008; Yuan et al., 2008), but whether they regulate endothelial junction integrity has not been studied.

In this study, we investigate the roles of each of the class I PI3K isoforms in endothelial barrier function and leukocyte TEM using siRNA and identify a key role for p110α in these processes through downstream effects on VE-cadherin Tyr phosphorylation, the Tyr kinase Pyk2, and the GTPase Rac.

Results

p110α regulates junctional morphology in endothelial cells

To investigate the roles of class I PI3K isoforms in regulating endothelial junctions, human umbilical vein endothelial cells (HUVECs) were transfected with siRNAs targeting p110α, -β, -γ, or -δ. Knockdown of each isoform did not affect the expression levels of the other isoforms or the regulatory subunit p85 (Fig. 1 A and Fig. S1, A and B). As a readout for PI3K activity, we monitored Akt phosphorylation at residues Ser473 and Thr308 (Vanhaesebroeck and Alessi, 2000; Vanhaesebroeck et al., 2001). Knockdown of p110α, -β, and -γ significantly reduced Akt phosphorylation (Fig. 1 A and Fig. S1 C). The strongest reduction was observed after p110γ depletion, which is consistent with observations in VEGF-stimulated mouse endothelial cells (Graupera et al., 2008), whereas p110β siRNA only had a small effect on total Akt phosphorylation, reflecting the very low levels of this isoform in endothelial cells (Graupera et al., 2008).

Control endothelial cells had a round cobblestone-like morphology with bundles of actin filaments predominantly around the edges of the cells (Fig. 1 B). VE-cadherin and PECAM-1 were localized linearly along cell–cell borders (continuous junctions; Fig. 1 B, arrow) and with a broader distribution where adjacent cells overlapped (overlapping junctions; Fig. 1 B, arrowheads); in these regions, VE-cadherin often had a unique reticular distribution (Fig. 1 B, boxed region in control; and Fig. S2 A; Lampugnani et al., 1995; Noria et al., 1999). As a measure of overlapping junctions, we used VE-cadherin staining to determine the junctional area per cell (junctional index; Fig. S2 B). Depletion of p110α but not p110β, -γ, or -δ increased the level of overlapping junctions (Fig. 1, B and C). This was not caused by a change in the shape of the cells because neither the spread area nor the circularity (circularity = 1 for a circle) were altered (Fig. 1, D and E).

p110α regulates endothelial responses to TNF

We have previously shown that TNF induces a progressive disruption of endothelial cell junctions and an increase in endothelial permeability and stress fibers over 8–24 h after stimulation (McKenzie and Ridley, 2007). TNF is also well known to induce endothelial elongation (Stolpen et al., 1986). Therefore, we investigated whether PI3Ks were activated by TNF and whether they affected TNF-induced responses. TNF transiently increased PI3K activity, as measured by Akt phosphorylation, at 10–30 min, which returned to basal levels at 60 min. It then gradually increased to 12–18 h (Fig. 2 A). This gradual increase correlated well with the time course of changes in endothelial cell morphology and cell–cell junctions (McKenzie and Ridley, 2007).

Cells treated with TNF for 18 h became elongated, and junctions were disrupted, particularly at the ends of elongated cells where VE-cadherin became fragmented (Figs. 2 B and 3 A). This indicates that junctions are strengthened when p110α is inhibited. These changes were not the result of altered expression of junctional proteins (Fig. S3 A). In contrast to p110α suppression, depletion of p110β, -γ, or -δ did not affect TNF-induced changes to cell–cell junctions or cell shape (Fig. 3, B–D; and Fig. S4, A and B). p110α depletion did not block all TNF-induced signaling because it did not affect early p38MAPK phosphorylation (5–60 min; Fig. S3 B). Interestingly, p110α expression increased gradually over 18 h after TNF addition (Fig. S3 C), which could contribute to the progressive changes to endothelial morphology and junctions.

In addition to alterations to cell–cell junctions and cell shape, TNF induced a dramatic increase in actin stress fibers aligned in parallel bundles along the longest axis of the
Inhibition of p110α increases junctional overlap in endothelial cells. (A) p110 siRNA-transfected HUVECs were lysed and analyzed by SDS-PAGE and blotting for PI3K subunits and Akt phosphorylation. siRNA oligonucleotides specifically knock down only individual isoforms and do not affect levels of the regulatory p85α subunit. GAPDH was used as a loading control. (B) Immunofluorescence micrographs of HUVECs transfected with p110α or control siRNA. Samples were stained with antibodies to VE-cadherin and PECAM-1 and Alexa Fluor 633–conjugated phalloidin to visualize F-actin. The arrow and arrowheads point to examples of linear and overlapping junctions, respectively. Bottom panels are magnifications of the boxed regions (merged images), showing detail of overlapping junctions. (C–E) Junctional index (junctional area/cell number; C), cell area (D), and cell circularity (E) were determined from immunofluorescence images using ImageJ software. In each case, a minimum of five fields were quantified (~20 cells per field) per experiment, and data represent the mean and SEM of at least three independent experiments. Statistical significance was assessed by the Mann-Whitney U test; *, P < 0.05. Bars, 20 µm.
Endothelial permeability is regulated by cell–cell junctions, and thus, we investigated whether the effect of p110α depletion on junctional organization correlated with a change in endothelial barrier function. TNF treatment progressively increased endothelial permeability to FITC-dextran, with an

**Figure 2.** Inhibition of p110α affects cell–cell junctions and cell morphology after TNF-mediated inflammation. (A) HUVECs were either stimulated with TNF (10 min to 18 h) or left unstimulated before lysis, SDS-PAGE, and Western blotting with pAktS473, Akt, and GAPDH antisera. (B) Immunofluorescence micrographs of HUVECs transfected with p110α or control siRNA and either stimulated with TNF (18 h) or left unstimulated before fixation. Samples were stained with antibodies to VE-cadherin and PECAM-1 and Alexa Fluor 633-conjugated phalloidin to visualize F-actin. Bottom panels are magnifications of the boxed regions (merged images), showing detail of a linear junction (untreated), disrupted junctions at the boundary of two elongated cells (TNF + si-control), or overlapping junctions (TNF + si-p110α). The arrowhead shows an example of an overlapping junction. Bars, 20 µm.

**p110α regulates endothelial permeability**

Endothelial permeability is regulated by cell–cell junctions, and thus, we investigated whether the effect of p110α depletion on junctional organization correlated with a change in endothelial barrier function. TNF treatment progressively increased endothelial permeability to FITC-dextran, with an
Regulates endothelial barrier function

Cain et al.

Endothelial p110α regulates leukocyte TEM

Leukocytes can cross the endothelium through the junctions (paracellular TEM) or through the endothelial cells (transcellular route). Endothelial junctional integrity is known to affect leukocyte paracellular TEM (Aghajanian et al., 2008). To assess whether PI3K inhibition affected leukocyte TEM, we initially measured TEM of THP-1 cells, a monococyte-like cell line which only utilizes the paracellular route in vitro (Fig. 5 A and not depicted). There was a significant reduction in THP-1 TEM across p110α-depleted HUVECs, whereas p110β and -γ did not affect TEM. Interestingly, p110β depletion induced a small reduction in TEM, which could reflect its postulated role in the selectin-mediated tethering of leukocytes to endothelial cells (Puri et al., 2004). To determine whether PI3Ks also affected transcellular TEM, we analyzed diapedesis of T cell lymphoblasts, which use both paracellular and transcellular pathways (Millán et al., 2006). The proportion of T lymphoblasts using the paracellular pathway was significantly reduced across p110α-depleted HUVECs, whereas transcellular TEM remained unaffected, which is consistent with a role for p110α in junctional regulation (Fig. 5 B). Transcellular TEM represented around 15% of TEM events, as previously observed (Millán et al., 2006), and was not affected by suppression of any p110 isoform.

To determine which step of leukocyte TEM was affected by p110α, we used a 3D assay system of HUVECs cultured on a thick collagen gel (Fig. 5 C). Depletion of endothelial cell p110α did not alter leukocyte adhesion after 10 or 60 min, and thus, differences in TEM were not caused by reduced cell attachment (Fig. 5, C and D). Indeed, expression of ICAM-1, a major leukocyte adhesion receptor up-regulated upon TNF stimulation, was not affected by p110α depletion (Fig. S1 A). Endothelial ICAM-1 is known to cluster around some adherent leukocytes (Barreiro et al., 2002; Carman and Springer, 2004), but this clustering was not affected by p110α levels (Fig. S4, C and D). However, p110α depletion reduced the number of cells able to transmigrate across the endothelium into the collagen gel matrix after 1 h (Fig. 5, C and E). Most adherent leukocytes on p110α siRNA–treated HUVECs appeared unable...
to cross endothelial junctions, as determined by staining with β-catenin (unpublished data). For those leukocytes that did cross the endothelium, their ability to invade the collagen matrix was similar (unpublished data), indicating that p110α depletion in endothelial cells does not alter leukocyte migration properties.

**p110α inhibition reduces VE-cadherin Tyr phosphorylation**

Tyr phosphorylation of VE-cadherin is believed to be an important factor in regulating vascular permeability and correlates with impaired barrier function (Dejana et al., 2008). TNF induced VE-cadherin Tyr phosphorylation (Fig. S5 A), which is consistent with previous observations (Angelini et al., 2006). p110α depletion reduced Tyr phosphorylation of VE-cadherin in TNF-stimulated cells (Fig. 6 A). Several Tyr residues in the VE-cadherin intracellular domain can be phosphorylated, including Y731, Y658, and Y685 (Allingham et al., 2007; Wallez et al., 2007; Turowski et al., 2008). To assess whether the p110α-regulated changes in total VE-cadherin phosphorylation were caused by one or more of these residues, lysates were blotted with phosphospecific antibodies for each of these sites. p110α siRNA–treated cells showed a strong reduction in Y731 phosphorylation and a smaller reduction at Y658 but no change at Y685 (Fig. 6 A), indicating that p110α regulates VE-cadherin Tyr phosphorylation on specific sites. It is also possible that the pY731 antibody recognizes other phospho-Tyr residues on VE-cadherin in addition to pY731 and that p110α regulates phosphorylation of these sites.

**p110α depletion reduces Pyk2 activity and its association with VE-cadherin**

Both Pyk2 and Src have been identified as potential Tyr kinases involved in the regulation of VE-cadherin phosphorylation (Allingham et al., 2007; Turowski et al., 2008). Pyk2 was present in VE-cadherin immunoprecipitates in unstimulated cells and at higher levels in TNF-stimulated cells, whereas its close relative FAK was not detected (Fig. 6 B and Fig. S5 A). Pyk2 association with VE-cadherin was much reduced in p110α-depleted cells, both in TNF-stimulated and unstimulated cells (Fig. 6 B and Fig. S5). In unstimulated cells, knockdown of p110γ also slightly reduced Pyk2–VE-cadherin association, suggesting that under some circumstances, p110γ could also affect junctional integrity, for example downstream of the G protein–coupled IL-8 receptor (Gavard et al., 2009), although not in the TNF response.

Y402 phosphorylation on Pyk2 reflects Pyk2 kinase activity (Mitra et al., 2005). TNF induced a small increase in Y402-Pyk2 at around 60 min and a larger increase at 12–18 h (Fig. 7), correlating with the delayed increase in PI3K activity induced by TNF (Fig. 2 A). Pyk2 Y402 phosphorylation was reduced by p110α suppression both in VE-cadherin immunoprecipitates and in total lysates, indicating that p110α regulates both Pyk2 from control is shown. Data represent the mean and SEM of three independent experiments performed in triplicate. Statistical significance was assessed by the Mann-Whitney U test; *, P < 0.05; ***, P < 0.02.
Figure 5. p110α inhibition in endothelial cells reduces leukocyte TEM. (A) THP-1 cells were added to TNF-stimulated, siRNA-transfected HUVECs grown in Transwell chambers, and the resultant TEM efficiency toward MCP-1 was determined after 1 h. (B) T lymphoblasts were added to TNF-stimulated, siRNA-transfected HUVECs and fixed after 15 min. Samples were analyzed by confocal microscopy and scored visually for paracellular and transcellular TEM events (Millán et al., 2006). (C) TNF-stimulated, p110α siRNA– or control siRNA–transfected HUVECs previously labeled with CellTracker orange dye were grown on collagen matrices in Transwell chambers. CellTracker green–labeled THP-1 cells were added to HUVECs, and TEM was allowed to proceed toward an MCP-1 gradient in the lower chamber for either 10 or 60 min before fixation; confocal z stacks were then collected. 3D reconstructions were produced using Velocity software. A small gamma correction was applied to the red channel to visualize weak cell tracker staining at the edges of cell, which are difficult to distinguish upon 3D rendering. (D and E) Quantification of adhesion to endothelial cells (D) or TEM (THP-1 cells within the collagen matrix) (E). Results represent the mean and SEM of at least three independent experiments. Statistical significance was assessed by the Mann-Whitney U test; *, P < 0.05; **, P < 0.02. Bars, 40 µm.
association with VE-cadherin and Pyk2 activation. Src was also detected in VE-cadherin immunoprecipitates, but unlike Pyk2, neither its levels nor its activity, as measured with antibodies to pY416-Src (Parsons and Parsons, 2004), were affected by p110 depletion (Fig. 6 B). p110 depletion did not induce reduced VE-cadherin binding to all its partners because the levels of β-catenin coimmunoprecipitated with VE-cadherin were not affected (Fig. 6 and Fig. S5 A).

The p85 subunit of PI3K has previously been reported to associate with Tyr phosphorylated VE-cadherin, which could be via p85 SH2 domains (Hudry-Clergeon et al., 2005). The level of p85 coimmunoprecipitation with VE-cadherin was increased by TNF stimulation (Fig. 6 B and Fig. S5 A), reflecting the higher VE-cadherin Tyr phosphorylation. The amount of p85 immunoprecipitated with VE-cadherin was strikingly reduced after p110 depletion, both with and without TNF stimulation (Fig. 6 B and Fig. S5 A), suggesting that PI3K-α activity itself regulates p85 association with VE-cadherin by increasing VE-cadherin Tyr phosphorylation.

Knockdown of p110α reduces Rac1 and RhoA activity
Rho GTPases are important regulators of endothelial barrier function (Wojciak-Stothard and Ridley, 2002; Fryer and Field, 2005; Tzima, 2006), and VE-cadherin has been implicated in the regulation of Rac1 activity (Lampugnani et al., 2002). In addition, PI3K isoforms affect Rho GTPase activity in endothelial and other cells (Papakonstanti et al., 2007; Graupera et al., 2008; Cain and Ridley, 2009). Therefore, we investigated whether p110α knockdown affected Rho, Rac, or Cdc42 activity. Despite being implicated in epithelial barrier function (Bruewer et al., 2004), active Cdc42 levels were not affected by
p110 knockdown (Fig. 8 A). In contrast, Rac1 and RhoA activities were both dramatically reduced in p110α-depleted HUVECs but not by knockdown of the other PI3K isoforms. Interestingly, of the Rho isoforms, only the level of GTP-RhoA was affected by p110α but not GTP-RhOB or -RhoC (Fig. 8 B).

VE-cadherin regulates the localization of the Rac guanine nucleotide exchange factor (GEF) Tiam-1 to endothelial cell–cell junctions (Lampugnani et al., 2002), and PI3Ks regulate Tiam-1 localization through its N-terminal pleckstrin homology domain (Sander et al., 1998). To assess whether PI3K-mediated changes in Rac1 or RhoA activity were linked to VE-cadherin, VE-cadherin immunoprecipitates from p110α-depleted HUVECs were probed for the Rac GEFs Tiam-1 and Vav and the Rho GEF GEF-H1, which has previously been reported to localize to endothelial junctions (McKenzie and Ridley, 2007). Although Vav and GEF-H1 could not be detected (not depicted), Tiam-1 associated with VE-cadherin in both unstimulated and TNF-stimulated endothelial cells, and levels were lower in p110α-depleted HUVECs (Fig. 8 C and Fig. S5). This suggests that p110α mediates Rac1 activation by regulating Tiam-1 association with VE-cadherin.

Rac1 and Pyk2 regulate endothelial barrier function and leukocyte TEM

Because p110α regulates both Rac1 and Pyk2 activities, we investigated whether they contributed to p110α-regulated barrier function in endothelial cells using siRNA to knock down their expression (Fig. 9 A). Both Pyk2 and Rac1 depletion reduced TNF-induced endothelial permeability (Fig. 9 B), whereas RhoA knockdown had no effect (Fig. S5). In addition, knockdown of Pyk2 or Rac1 in HUVECs reduced THP-1 TEM, and this effect was significant when both Pyk2 and Rac1 were depleted (Fig. 9 D). Interestingly, Pyk2 and Rac1 each had different effects on endothelial morphology that could affect barrier function. Like p110α suppression, Pyk2-depleted cells had an increase in overlapping cell junctions and junctional index, both in stimulated and unstimulated cells, whereas Rac1 knockdown did not affect junctional index (Fig. 9 E and not depicted). In contrast, Rac1 and p110α but not Pyk2 depletion inhibited TNF-induced cell elongation (circularity; Fig. 9, C and F), which reduced the disruption of junctions observed at the ends of elongated cells (Fig. 2 B). Knockdown of both Rac1 and Pyk2 inhibited cell elongation and increased overlapping junctions (Fig. 9, E and F), although stress fibers were still induced, which is consistent with results with p110α depletion (Fig. 2 B). These results indicate for the first time that TNF-induced changes to cell shape and junction morphology are regulated separately and that both of these responses are likely to affect barrier function.

Discussion

PI3Ks have been shown to regulate vascular integrity and angiogenesis during development, but the mechanistic basis for their effects on endothelial cells has not been determined. In this study, we have identified a specific role for p110α in regulating endothelial junctions, affecting both TNF-induced endothelial permeability and leukocyte TEM. Our results indicate that p110α acts via VE-cadherin Tyr phosphorylation, the Tyr kinase Pyk2, and the Rho GTPase Rac1 to regulate these responses.

Tyr phosphorylation of the intracellular domain of VE-cadherin leads to protein binding and correlates with increased endothelial permeability and TEM (Lambeng et al., 2005; Potter et al., 2005; Turowski et al., 2008). Our data indicate that p110α plays a key role in the assembly of a VE-cadherin signaling complex by regulating Tyr phosphorylation of VE-cadherin residue Y731, with a smaller effect on Y658. Several kinases contribute to VE-cadherin phosphorylation, including Pyk2 and Src family kinases, and a dominant-negative Pyk2 construct was shown to affect junctional integrity (Weis et al., 2004; van Buul et al., 2005; Allingham et al., 2007; Wallez et al., 2007). In agreement with this, we find that knockdown of Pyk2 reduces both endothelial permeability and leukocyte TEM. We show in this study for the first time that p110α acts upstream of Pyk2 and regulates both Pyk2 autophosphorylation and its association with VE-cadherin. Like its close relative FAK, Pyk2 autophosphorylation recruits Src kinases (Basile et al., 2007). VE-cadherin Y731 is a putative Pyk2 target (Dejana et al., 2008), although it is unclear whether Pyk2 is able to directly phosphorylate VE-cadherin in vivo or whether it acts indirectly, for example by recruiting a Src kinase such as Fyn, which has been reported to mediate TNF-induced Tyr phosphorylation of VE-cadherin (Angelini et al., 2006). As Pyk2 has no SH2 domain, it is unlikely to bind directly to phosphorylated tyrosines in VE-cadherin, but it could be recruited via the p85 regulatory subunit of PI3K. We show that p85 associates with VE-cadherin and PI3K interacts with Pyk2 (Melikova et al., 2004), probably via the interaction of a p85 SH2 domain with a Pyk2 phospho-Tyr (van Buul et al., 2005; Allingham et al., 2007). Interestingly, p85 interaction with VE-cadherin is reduced by p110α inhibition, presumably because p85 association with the complex depends on PI3K-α–mediated VE-cadherin Tyr phosphorylation.

Our data suggest that p110α regulates Rac activity via recruitment of the Rac GEF Tiam-1 to the VE-cadherin complex. Recruitment of Tiam-1 to membranes in endothelial cells is dependent on VE-cadherin (Lampugnani et al., 2002), and the N-terminal pleckstrin homology domain of Tiam-1

Figure 7. Pyk2 activity is increased by TNF stimulation. Endothelial cells were either stimulated with TNF (10 min to 18 h) or left unstimulated before lysis, SDS-PAGE, and immunoblotting with pY402-Pyk2, Pyk2, and GAPDH antisera.
binds to PtdIns(3,4,5)P_3 (Hordijk et al., 1997; Michiels et al., 1997). Association of p110α via p85 with VE-cadherin might thereby provide a mechanism by which Tiam-1 is recruited and activates Rac1.

p110α inhibition prevents two TNF-induced morphological responses that could be linked to endothelial barrier function, cell junction morphology, and cell elongation via Pyk2 and Rac1, respectively. p110α and Pyk2 depletion both lead to an increase in adherens junction staining, predominantly in regions where endothelial cells overlap. These junction-rich regions are likely to form a strong barrier to both small molecules and leukocytes. In contrast, Rac1 mediates TNF-induced elongation and contributes to permeability and leukocyte TEM, indicating that cell shape affects barrier function. This could be because in elongated cells, stress fibers exert a higher tension on cell–cell junctions and thus decrease junctional integrity at cell poles compared with cells with a more cobblestone shape. Indeed, leukocytes preferentially transmigrate at poles of elongated endothelial cells (Millán et al., 2006), and endothelial shape changes have been proposed to contribute to TNF-induced vascular leakage in vivo (Cotran and Pober, 1990). Interestingly, RhoA-depleted cells did not show a reduction in TNF-induced stress fibers or altered barrier function. This is consistent with our previous results suggesting that TNF-induced stress fiber assembly and endothelial permeability do not correlate with RhoA activation (McKenzie and Ridley, 2007).

Previous studies have suggested that PI3Ks are important for efficient TEM in vivo and in vitro (Puri et al., 2004, 2005; Nakhaei-Nejad et al., 2007). In vitro, treatment of HUVECs with pan-PI3K inhibitors did not affect lymphocyte adhesion but reduced diapedesis. Our results indicate that this step specifically involves p110α. In vivo studies with gene-targeted mice have implicated endothelial p110γ and -δ in selectin-mediated neutrophil tethering and rolling but not ICAM-1–mediated firm attachment to endothelial cells (Puri et al., 2004, 2005), and indeed, we see a small effect of p110α on leukocyte TEM in our model, which is consistent with an involvement in selectin function. So far, the roles of p110β or -α have not been tested in vivo. Collectively, these results and our data indicate that p110α acts in endothelial cells primarily to regulate changes in junctional integrity induced by TNF and thus influence leukocyte diapedesis, whereas p110γ and -δ are involved in selectin-mediated leukocyte tethering. It is also possible that p110α affects adhesion receptor signaling in some way that reduces subsequent TEM.

In conclusion, we have shown that the p110α isoform of PI3K specifically regulates cell–cell contacts in endothelial cells, thereby contributing to TNF-induced changes to endothelial barrier function and leukocyte TEM. This selective

Figure 8. p110α depletion decreases RhoA and Rac but not Cdc42 activity. (A and B) TNF-stimulated, p110α siRNA-transfected HUVECs were lysed, and Rho GTPase activity was determined by affinity for GST-Rho-kin RBD– or GST-PAK1-PBD–conjugated beads for RhoA/B/C and Rac/Cdc42, respectively. After washing, samples were separated by SDS-PAGE and analyzed by Western blotting with antibodies to Rac1 or Cdc42 [A] or RhoA, -B, or -C [B]. Total lysates (bottom) of each sample were Western blotted in parallel to control for total amounts of GTPase. GAPDH was used as a loading control. (C) PI3K inhibition reduces Tiam-1 association with VE-cadherin.
role of p110α in endothelial cells could in part explain its role to angiogenesis (Graupera et al., 2008), which requires dynamic changes to endothelial cell–cell junctions and shape. Our results suggest that p110α-selective inhibitors could be used to treat chronic inflammatory diseases involving TNF such as arthritis and atherosclerosis.

Figure 9. Pyk2 and Rac1 depletion alter endothelial junctions and leukocyte TEM. HUVECs were transfected with either control siRNA or siRNA to Pyk2 and/or Rac1 and then stimulated with TNF (18 h) or left unstimulated. (A) HUVECs were lysed and analyzed by SDS-PAGE and Western blotting with Pyk2, Rac1, and GAPDH antibodies to assess siRNA knockdown efficiency and ICAM-1 to assess TNF stimulation. The asterisk indicates a nonspecific band; Rac1 is the top band. (B) Barrier function of siRNA-treated HUVECs either stimulated with TNF (16–18 h) or left unstimulated was assessed by permeability to FITC-dextran. Unstimulated monolayers were assigned as 100%. (C) Immunofluorescence micrographs of siRNA-transfected HUVECs. Samples were stained with antibodies to VE-cadherin and Alexa Fluor 633-conjugated phalloidin to visualize F-actin. Arrowheads indicate examples of overlapping junctions. (D) THP-1 cells were added to siRNA-treated, TNF-stimulated HUVECs in Transwell chambers, and the resultant TEM efficiency toward MCP-1 was determined after 1 h. (E and F) Junctional index (junctional area/cell number; E) and cell circularity (F) were determined from immunofluorescence images. Data represent the mean and SEM of at least four independent experiments, each performed in triplicate. Statistical significance was assessed by the Mann-Whitney U test; *, P < 0.05; **, P < 0.02. Bars, 20 µm.

Materials and methods

Antibodies and reagents
Antibodies to p110α, β, γ, and δ have been previously described (Graupera et al., 2008; Guillermet-Guibert et al., 2008). Antibodies to ZO-1, -2, and -3, JAM-A, occludin, VE-cadherin—Y731, and claudin-5 were purchased from Invitrogen, α- and β-catenin and β-actin were...
purchased from Sigma-Aldrich; VE-cadherin, p120-catenin, and phospho-
p120-catenin were obtained from BD; RhoA, -B, -C and C-tiam-1 were purchased from Santa Cruz Biotechnology, Inc.; Akt, pAktS473, pAktT308, Pyk2, and Pyk2Y4204 were obtained from Cell Signaling Technology; VE-
cadherin–Y658, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and p85 were obtained from Millipore; VE-cadherin–Y685 was purchased from ECM Biosciences; ICAM-1 was obtained from R&D systems; and PECAM-1 was obtained from Dako. FITC-dextran was obtained from Sigma-Aldrich, and TNF was obtained from PeproTech. CellTracker orange and CellTracker green dyes were purchased from Invitrogen.

Cell culture

Pooled HUVECs were purchased from Lonza and cultured in EGM-2 medium (Lonza) containing 3% FCS. Cells were used for experiments between passages 1 and 4 and were seeded onto fibronectin-coated (10 µg/ml; Sigma-Aldrich) flasks, glass coverslips, or filters. For experiments, HUVECs were stimulated with 10 ng/ml TNF for 18 h except where indicated. THP-1 cells were maintained in suspension culture in RPMI 1640 medium (Invitrogen) containing 10% FCS and 2 mM L-glutamine at between 5 × 10^4 and 2 × 10^5/ml. THP-1 lymphoblasts were prepared from isolated human peripheral blood mononuclear cells (peripheral blood lymphocytes). After stimulation with 0.5% phytohemagglutinin for 48 h, nonadherent peripheral blood lymphocytes were washed and cultured in RPMI 1640 medium (10% FCS and 2 U/ml IL-2 in 5% CO2) and used in experiments after culturing for 7–12 d.

siRNA transfection

HUVECs were seeded at 10^4 cells per well in 6-well dishes 24 h before transfection. Four individual siRNA oligonucleotides (Thermo Fisher Scientific) targeting each of the human p110α (D-003018-05, D-003018-06, D-003018-08, and D-003018-09), p120 (D-003019-09, D-003019-07), and p85α (D-003019-09, D-003019-07, D-005274-04, D-005274-05, p110α (D-003018-08, D-003018-09, D-003019-09, D-005274-04, D-005274-05), or p110β (D-006775-05, D-006775-06, D-006775-07, and D-006775-08) catalytic subunits or oligonucleotides targeting RhoA (D-003860-01 and D-003860-03), Rac1 (D-003560-05 and D-003560-07), Pyk2 (L-003165-00), or VE-cadherin (D-003641-03) were tested for knockdown activity by Western blotting and subsequently used in all subsequent experiments. siRNA-transfected HUVECs were plated at confluence on dishes containing gold matrices, and cell numbers were determined by comparison with a standard curve of known voxcell numbers.

Immunofluorescence microscopy

HUVECs grown to confluence on glass coverslips were fixed with 3.7% formaldehyde, permeabilized with 0.2% Triton-X 100 in PBS (15 min), blocked with 3% BSA in PBS (1 h), and then incubated with primary antibodies in 3% BSA in PBS (1 h). Samples were sequentially incubated for 1 h with Alexa Fluor 488– or Alexa Fluor 546–conjugated anti–rabbit or anti–mouse IgG secondary antibodies, followed by incubation with Alexa Fluor 633–conjugated phalloidin (20 min; Invitrogen). Coverslips were mounted using ProLong Antifade reagent (Invitrogen). Images were acquired at room temperature using a confocal microscope (LSM 510 META; Carl Zeiss, Inc.) with three single photomultiplier tube confocal detectors mounted on an inverted microscope (Axio 

software analysis options (Fig. S2 B). In each case, a minimum of five fields were quantified (−20 cells per field) per experiment, and data shown represent the mean of at least three independent experiments.

TEM assay

HUVECs were plated at confluence on Transwell inserts (5-µm pore). After 6–8 h, cells were treated with 10 ng/ml TNF for 18 h. 10 µg/ml MCP-1 was added to the bottom compartment. After the addition of 1 × 10^5 washed THP-1 cells to the upper chamber. Cells were left to transmigrate (1 h; 37°C) before medium from the bottom chamber was removed, and cells were counted using a cell counter (CASY; Innovatis). Each experiment was performed in triplicate. For quantification of T lymphoblast paracellular and transcellular TEM events, T lymphoblasts (provided by E. Cernuda-Morollon, University College London, London, England, UK) were added to confluent TNF-stimulated HUVECs on glass coverslips for 15 min before fixation with 4% paraformaldehyde. Samples were stained with anti–ICAM-1/ Alexa Fluor 488–conjugated anti–mouse IgG, anti–β-Catenin/Alexa Fluor 546–conjugated anti–rabbit, and Alexa Fluor 633–conjugated phalloidin. T lymphoblasts undergoing TEM were easily distinguishable by confocal microscopy, as the leading edge was in contact with the coverslip, whereas the rear uropod was still localized on the surface of the endothelial cell. β-Catenin and ICAM-1 staining was used to determine whether the cell was undergoing paracellular or transcellular diapedesis, respectively. Each experiment was performed in quadruplicate, quantifying 25 fields per condition.

3D model for TEM

HUVECs were seeded at confluence onto collagen I gels polymerized in 12-µm pore Transwell filters. After 6–8 h, monolayers were treated with 10 ng/ml TNF for 18 h. HUVECs were labeled with 5 µM CellTracker orange for 40 min before washing in normal medium. 10 µg/ml MIP-1 was added to the bottom chamber before the addition of 1 × 10^5 washed CellTracker green–labeled THP-1 cells to the upper chamber. After 10 or 60 min, HUVECs were washed three times to remove unbound THP-1 cells, and then Transwells were fixed by immersion in 3.7% (wt/vol) paraformaldehyde before being processed for immunofluorescence microscopy. z sections were acquired at 200-nm intervals by confocal microscopy (see Immunofluorescence microscopy), and 3D images were reconstructed using Velocity image analysis software (PerkinElmer). Adhesion and TEM (leukocytes below the level of the endothelial cells) were assessed using image software to count CellTracker green voxels either above or within the matrix, and cell numbers were determined by comparison with a standard curve of known voxcell numbers.

Transendothelial permeability assays

HUVECs were seeded onto 0.4-µm pore Transwell filters (Thermo Fisher Scientific) at confluence. After 6–8 h, monolayers were treated with 10 ng/ml TNF for 18 h. 0.1 µg/ml FITC-dextran (molecular weight, 42,000) was subsequently applied to the apical chamber and allowed to equilibrate for 45 min before a sample of the medium was removed from the lower chamber to measure basal permeability. Fluorescence was measured using a fusion universal microplate analyzer (Fusion-FA; PerkinElmer; excitation, 492 nm; detection, 520 nm), and data were expressed as a ratio of the control untreated monolayer fluorescence. All experiments were performed in triplicate, and results shown are the mean of at least four independent experiments.

TER measurement

Transfected HUVECs were plated at confluence on dishes containing gold electrodes (ECIS; Applied Biophysics). After 24 h, cells were washed in warm EGM-2 media and either treated with 10 ng/ml TNF for 18 h or left untreated before data were collected on a resistance meter (ECIS 1600; Applied Biophysics). Resistance data were collected at a constant voltage of 15 V for a period of 12 h, sampling data every 10 min. Data from a stable period of 4–6 h were used to calculate mean resistance. Control siRNA transfection did not alter the TNF-induced decrease in resistance.

Rho, Rac, and Cdc42 activity assays

Pull-down activity assays were performed using either GST-Rhotekin RBD beads (Cytoskeleton, Inc.; 50 µg per pull-down for Rho) or GST-PKAK- PBD agarose conjugate (Millipore; 10 µg per pull-down for Rac/Cdc42). 7 × 10^6 cells per condition were lysed rapidly in pull-down buffer (50 mM Tris, pH 7.5, 1% Triton X-100, 0.5% Na deoxycholate, 0.1% SDS, 500 mM NaCl, 100 mM MgCl2). 10 µg/ml leupeptin, 10 µg/ml aprotinin, 1 mM PMSF, 10% glycerol, and 1 mM DTT) before transferring to a microfuge tube (Fresco 17 centrifuge; Thermo Fisher Scientific) and centrifuging (12,000 g;
In a novel endothelial docking structure for adherent leukocytes. J. Cell Biol. 157:1233–1245. doi:10.1083/jcb.200112126

Basilé, J.R., G. Gavard, and J.S. Gutkind. 2007. Plexin-B1 utilizes Rhoa and Rho kinase to promote the integrin-dependent activation of Akt and ERK and endothelial cell motility. J. Biol. Chem. 282:34888–34895. doi:10.1074/jbc.M705046200

Bäumer, S., L. Keller, A. Holtmann, R. Funke, B. August, A. Gamp, H. Wölburg, K. Wölburg-Buchholz, U. Deutsch, and D. Vestweber. 2006. Vascular endothelial cell-specific phosphotyrosine phosphatase (VE-PTP) activity is required for blood vessel development. Blood. 107:4745–4762. doi:10.1182/blood-2006-11-0241

Birukova, K.G. 2009. Small GTPases in mechanosensitive regulation of endothelial barrier. Microvasc. Res. 77:46–52. doi:10.1016/j.mvr.2008.09.006

Birukova, A.A., K.G. Birukov, B. Gorskho, F. Liu, J.G. Garcia, and A.D. Verin. 2005. MAP kinases in lung endothelial permeability induced by microtubule disassembly. Am. J. Physiol. Lung Cell. Mol. Physiol. 289:L75–L84. doi:10.1152/ajplung.00447.2004

Bruewer, M., A.M. Hopkins, M.E. Hobert, A. Nusrat, and J.L. Madara. 2004. RhoA, Rac1, and Cdc42 exert distinct effects on epithelial barrier via selective structural and biochemical modulation of junctional proteins and F-actin. Am. J. Physiol. Cell Physiol. 287:C327–C335. doi:10.1152/ajpcell.00887.2004

Cain, R.J., and A.J. Ridley. 2009. Phosphoinositide 3-kinases in cell migration. Biol. Cell. 101:13–29. doi:10.1042/BC20080079

Carman, C.V., and T.A. Springer. 2004. A transmigratory cup in leukocyte diapedesis both through individual vascular endothelial cells and between them. J. Cell Biol. 167:377–388. doi:10.1083/jcb.200401429

Carmeliet, P., M.G. Lambuagni, L. Moons, F. Breviario, V. Compernolle, F. Bono, G. Balconi, R. Spagnuolo, B. Oosthuyse, M. Dewerchin, et al. 1999. Targeted deficiency of c-src tyrosine truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell. 98:147–157. doi:10.1016/S0092-8674(00)81010-7

Corada, M., M. Mariotti, G. Thurston, K. Smith, R. Kunkel, M. Brockhaus, M.G. Lambuagni, I. Martin-Padura, A. Stoppacciaro, L. Ruco, et al. 1999. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc. Natl. Acad. Sci. USA. 96:9815–9820. doi:10.1073/pnas.96.19.9815

Cotran, R.S., and J.S. Boerer. 1990. Cytokine-endothelial interactions in inflammation, immunity, and vascular injury. J. Am. Soc. Nephrol. 1:225–235.

Dejana, E., F. Orsenigo, and M.G. Lambuagni. 2008. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J. Cell Sci. 121:2115–2122. doi:10.1242/jcs.017897

Engelhardt, B., and H. Wölburg. 2004. Mini-review: Transendothelial migration of leukocytes: through the front door or around the side of the house? Eur. J. Immunol. 34:2955–2963. doi:10.1002/eji.200425327

Esser, S., M.G. Lambuagni, M. Corada, E. Dejana, and W. Risau. 1998. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J. Cell Sci. 111:1853–1865.

Essler, M., K. Hermann, M. Amano, K. Kaibuchi, J. Heesemann, P.C. Weber, and M. Aebischer. 1998. Pasteurella multocida toxin increases endothelial permeability via Rho kinase and myosin light chain phosphatase. J. Immunol. 161:5640–5646.

Fryer, B.H., and J. Field. 2005. Rho, Rac and Pak and angiogenesis: old roles and newly identified responsibilities in endothelial cells. Cancer Lett. 229:13–23. doi:10.1016/j.canlet.2004.12.009

Gavard, J., X. Hou, Y. Qu, A. Masedunskas, D. Martin, R. Weigert, X. Li, and J.S. Gutkind. 2009. A role for a CXCR2/phosphatidylinositol 3-kinase γ signaling axis in acute and chronic vascular permeability. Mol. Cell. Biol. 29:2469–2480. doi:10.1128/MCB.01304-08

Graupera, M., J. Guillerm-Guibert, L.C. Foukas, L.K. Phng, R.J. Cain, A. Salpekar, W. Pearce, S. Meek, J. Millan, P.R. Catillas, et al. 2008. Angio genesis selectively requires the p110α isoform of PI3K to control endothelial cell migration. Nature. 453:662–666. doi:10.1038/nature06892

Guillerm-Guibert, J., K. Bjorklof, A. Salpekar, C. Gonella, F. Ramadani, A. Bilancio, S. Meek, M. Brockhaus, M.G. Lampuagni, J. Heesemann, P.C. Weber, and M. Aebischer. 2008. The p110β isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110γ. Proc. Natl. Acad. Sci. USA. 105:8292–8297. doi:10.1073/pnas.0707761105

Gumbiner, B.M. 2005. Regulation of cadherin-mediated adhesion in morphogenesis. Nat. Rev. Mol. Cell Biol. 6:622–634. doi:10.1038/nrm1699

Hordijk, P.L., J.P. ten Klooster, R.A. van der Kamen, F. Michiels, L.C. Oomen, and J.G. Collard. 1997. Inhibition of invasion of endothelial cells by Tiam1-Rac signaling. Science. 278:1464–1466. doi:10.1126/science.278.5342.1464

Hordijk, P.L., E. Anthony, F.P. Mul, R. Rentsma, L.C. Oomen, and D. Roos. 1999. Vascular-endothelial-cadherin modulates endothelial monolayer permeability. J. Cell Sci. 112:1915–1923.
Puri, K.D., T.A. Doggett, C.Y. Huang, J. Douangpanya, J.S. Hayflick, F. Michiels, and J.G. Collard. 1998. Matrix-dependent Tiam1/Rac signaling in epithelial cells promotes either cell-cell adhesion or cell migration and is regulated by phosphatidylinositol 3-kinase. *J. Cell Biol.* 143:1385–1398. doi:10.1083/jcb.143.4.1385

Serban, D., J. Leng, and D. Cheres. 2008. H-ras regulates angiogenesis and vascular permeability by activation of distinct downstream effectors. *Circ. Res.* 102:1350–1358. doi:10.1161/CIRCRESAHA.107.196664

Shasby, D.M., D.R. Ries, S.S. Shasby, and M.C. Winter. 2002. Histamine stimulates phosphorylation of adherens junction proteins and alters their link to vimentin. Am. J. Pathol. 161:973–984. doi:10.1016/S0002-8841(02)01385-5

Stolpen, A.H., E.C. Guinan, W. Fiers, and J.S. Pober. 1986. Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am. J. Pathol. 123:16–24.

Suire, S., J. Coadwell, G.J. Ferguson, K. Davidson, P. Hawkins, and L. Stephens. 2005. P64-a new Hbetagamma-activated regulatory subunit of the type IB phosphoinositide 3-kinase p110 Subtype. J. Biol. Chem. 280:21129–21136. doi:10.1074/jbc.M50556820

Tamura, S., M. Nakhaei-Nejad, A.M. Hussain, Q.-X. Zhang, and A.G. Murray. 2007. Regulation of transendothelial permeability by phosphoinositide 3-kinase gamma activity in neutrophil trafficking. *JCB*. 196:556–560. doi:10.1061/jcb.2005.02.020

Turowski, P., R. Martinelli, R. Crawford, D. Wateridge, A.P. Papageorgiou, M.G. Lampugnani, A.C. Gamp, D. Westveber, P. Adamson, E. Dejana, and J. Greenwood. 2008. Phosphorylation of vascular endothelial cadherin controls lymphocyte emigration. J. Cell Sci. 121:29–37. doi:10.1242/jcs.022681

Tzima, E. 2006. Role of small GTPases in endothelial cytoskeletal dynamics and the shear stress response. Circ. Res. 98:176–185. doi:10.1161/01.RES.0000220134.21996.1B

van Buul, J.D., E.C. Anthony, M. Fernandez-Borja, K. Burridge, and P.L. Hordijk. 2005. Proline-rich tyrosine kinase 2 (Pyk2) mediates vascular endothelial-cadherin-based cell-cell adhesion by regulating beta-catenin phosphorylation. J. Biol. Chem. 280:21129–21136. doi:10.1074/jbc.M50089820

van Gils, J.M., J. Suttertmer, T.J. van Duijn, J.J. Kwagga, L. Porcelijn, M. de Haas, and P.L. Hordijk. 2009. HPA-1a alloantibodies reduce endothelial cell spreading and monolayer integrity. Mol. Immunol. 46:406–415. doi:10.1016/j.molimm.2008.10.015

van Wetering, S., N. van den Berk, J.D. van Buul, F.P. Mul, I. Lommenre, R. Mous, J.P. ten Klooster, J.J. Zwagigma, and P.L. Hordijk. 2008. HPA-1a alloantibodies reduce endothelial cell spreading and monolayer integrity. Mol. Immunol. 46:406–415. doi:10.1016/j.molimm.2008.10.015

Weis, S., S. Shintani, A. Weber, R. Kirchmair, M. Wood, A. Cravens, H. McSharry, A. Iwakura, Y.S. Yoon, N. Himes, et al. 2004. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J. Clin. Invest. 113:885–894.

Wojciak-Stothard, B., and A.J. Ridley. 2002. H-Ras regulates angiogenesis and vasculature by activation of distinct downstream effectors. Circ. Res. 102:1350–1358. doi:10.1161/CIRCRESAHA.107.196664

Yuan, T.L., H.S. Choi, A. Matsui, C. Benes, E. Lifshits, J. Luo, J.V. Frangioni, J. de Haas, and P.L. Hordijk. 2009. HPA-1a alloantibodies reduce endothelial cell spreading and monolayer integrity. Mol. Immunol. 46:535–602. doi:10.1016/j.molimm.2008.10.015

Zou-Yenou, J.L., C. Faivre, A. Eck, G. Nacher, and E. Hoffmann. 2007. The cAMP-PKA pathway regulates Rac1 activation in peritoneal neutrophils. J. Immunol. 178:229–236. doi:10.4049/jimmunol.178.0.023

Zou-Yenou, J.L., C. Faivre, G. Nacher, and E. Hoffmann. 2007. The cAMP-PKA pathway regulates Rac1 activation in peritoneal neutrophils. J. Immunol. 178:229–236. doi:10.4049/jimmunol.178.0.023